Biomarkers for cystic fi brosis drug development

Purpose: To provide a review of the status of biomarkers in cystic fibrosis drug development, including regulatory definitions and considerations, a summary of biomarkers in current use with supportive data, current gaps, and future needs. Methods: Biomarkers are considered across several areas of CF drug development, including cystic fibrosis transmembrane conductance regulator modulation, infection, and inflammation. Results: Sweat chloride, nasal potential difference, and intestinal current measurements have been standardized and examined in the context of multicenter trials to quantify CFTR function. Detection and quantification of pathogenic bacteria in CF respiratory cultures (e.g.: Pseudomonas aeruginosa) are commonly used in early phase antimicrobial clinical trials, and to monitor safety of therapeutic interventions. Sputum (e.g.: neutrophil elastase, myeloperoxidase, calprotectin) and blood biomarkers (e.g.: C reactive protein, calprotectin, serum amyloid A) have had variable success in detecting response to inflammatory treatments. Conclusions: Biomarkers are used throughout the drug development process in CF, and many have been used in early phase clinical trials to provide proof of concept, detect drug bioactivity, and inform dosing for later-phase studies. Advances in the precision of current biomarkers, and the identification of new biomarkers with ‘omics-based technologies, are needed to accelerate CF drug development. © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

[1]  J. Clancy,et al.  Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2]  J. Clancy,et al.  Cystic Fibrosis and Its Management Through Established and Emerging Therapies. , 2016, Annual review of genomics and human genetics.

[3]  S. Stanojevic,et al.  Physiologic endpoints for clinical studies for cystic fibrosis. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[4]  W. T. Harris,et al.  Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. , 2016, The Lancet. Respiratory medicine.

[5]  F. Accurso,et al.  Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[6]  S. Stanojevic,et al.  Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[8]  S. Molin,et al.  Diversity of metabolic profiles of cystic fibrosis Pseudomonas aeruginosa during the early stages of lung infection. , 2015, Microbiology.

[9]  R. Fischer,et al.  A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[10]  S. McColley,et al.  Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. , 2015, The Lancet. Respiratory medicine.

[11]  S. Heltshe,et al.  Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation. , 2015, Annals of the American Thoracic Society.

[12]  Zaid Abdo,et al.  The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation , 2015, Microbiome.

[13]  R. Ng,et al.  Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry , 2015, Thorax.

[14]  C. Goss,et al.  Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[15]  J. Harris,et al.  Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. , 2015, Annals of the American Thoracic Society.

[16]  D. Porteous,et al.  Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis. , 2015, American journal of respiratory and critical care medicine.

[17]  P. Hiatt,et al.  Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[18]  Umer Khan,et al.  Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. , 2014, American journal of respiratory and critical care medicine.

[19]  S. Peltz,et al.  Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Respiratory medicine.

[20]  S. McColley,et al.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. , 2014, The Lancet. Respiratory medicine.

[21]  M. Milburn,et al.  Serum metabolomics indicate altered cellular energy metabolism in children with cystic fibrosis , 2014, Pediatric pulmonology.

[22]  R. Ware,et al.  Risk Factors for Bronchiectasis in Children With Cystic Fibrosis , 2014 .

[23]  Forest Rohwer,et al.  Biogeochemical Forces Shape the Composition and Physiology of Polymicrobial Communities in the Cystic Fibrosis Lung , 2014, mBio.

[24]  Waldemar Swiercz,et al.  Automated CT scan scores of bronchiectasis and air trapping in cystic fibrosis. , 2014, Chest.

[25]  J. Clancy,et al.  Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[26]  Robert Schmieder,et al.  Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation , 2014, The ISME Journal.

[27]  J. M. Dow,et al.  Microbiota and Metabolite Profiling Reveal Specific Alterations in Bacterial Community Structure and Environment in the Cystic Fibrosis Airway during Exacerbation , 2013, PloS one.

[28]  F. van Goor,et al.  The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[29]  Barbara A. Bailey,et al.  Clinical Insights from Metagenomic Analysis of Sputum Samples from Patients with Cystic Fibrosis , 2013, Journal of Clinical Microbiology.

[30]  A. Webb,et al.  Sweat chloride is not a useful marker of clinical response to Ivacaftor , 2013, Thorax.

[31]  D. Sin,et al.  Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. , 2013, Chest.

[32]  R. Szczesniak,et al.  Multicenter Intestinal Current Measurements in Rectal Biopsies from CF and Non-CF Subjects to Monitor CFTR Function , 2013, PloS one.

[33]  J. Clancy,et al.  Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation , 2013, PloS one.

[34]  L. Kent,et al.  Clinimetric properties of bronchoalveolar lavage inflammatory markers in cystic fibrosis , 2013, European Respiratory Journal.

[35]  M. Ballmann,et al.  Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. , 2013, American journal of respiratory and critical care medicine.

[36]  P. Sterk,et al.  Exhaled breath analysis by electronic nose in airways disease. Established issues and key questions , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[37]  R. Le Berre,et al.  Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis , 2013, BMC Microbiology.

[38]  M. Strand,et al.  Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis , 2013, Thorax.

[39]  J. Mainz,et al.  Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. , 2013, American journal of respiratory and critical care medicine.

[40]  D. Hansell,et al.  Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation , 2013, Thorax.

[41]  B. Chowdhury,et al.  Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. , 2013, Chest.

[42]  S. Sagel,et al.  Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. , 2012, American journal of respiratory and critical care medicine.

[43]  G. Döring,et al.  Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study , 2012, Thorax.

[44]  L. Saiman,et al.  Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. , 2012, Chest.

[45]  T. Liou,et al.  Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. , 2012, Chest.

[46]  R. Keogh,et al.  Sputum Biomarkers and the Prediction of Clinical Outcomes in Patients with Cystic Fibrosis , 2012, PloS one.

[47]  A. Cantin,et al.  Plasma biomarkers and cystic fibrosis lung disease. , 2012, Clinical and investigative medicine. Medecine clinique et experimentale.

[48]  B. Morrissey,et al.  Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. , 2012, Free radical biology & medicine.

[49]  S. Plafker,et al.  Interaction with CREB binding protein modulates the activities of Nrf2 and NF-κB in cystic fibrosis airway epithelial cells. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[50]  Susan Murray,et al.  Decade-long bacterial community dynamics in cystic fibrosis airways , 2012, Proceedings of the National Academy of Sciences.

[51]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[52]  D. Kerr,et al.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.

[53]  O. Eickelberg,et al.  The Chitinase-Like Protein YKL-40 Modulates Cystic Fibrosis Lung Disease , 2011, PloS one.

[54]  J. Clancy,et al.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.

[55]  Todd A. Durham,et al.  Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. , 2011, American journal of respiratory and critical care medicine.

[56]  M. Proesmans,et al.  Change in IgG and evolution of lung function in children with cystic fibrosis. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[57]  J. Emerson,et al.  Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection , 2011, Pediatric pulmonology.

[58]  S. McColley,et al.  Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis , 2011, Clinical Microbiology Reviews.

[59]  S. Willsie.  Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation , 2011 .

[60]  J. Clancy,et al.  Measurement of ion transport function in rectal biopsies. , 2011, Methods in molecular biology.

[61]  J. Harris,et al.  Reliability of Quantitative Real-Time PCR for Bacterial Detection in Cystic Fibrosis Airway Specimens , 2010, PloS one.

[62]  J. Carlin,et al.  Identifying peroxidases and their oxidants in the early pathology of cystic fibrosis. , 2010, Free radical biology & medicine.

[63]  R. Gibson,et al.  An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis , 2010, Pediatric pulmonology.

[64]  J. Clancy,et al.  An international randomized multicenter comparison of nasal potential difference techniques. , 2010, Chest.

[65]  Antonia Zapf,et al.  Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data , 2010, Thorax.

[66]  Christine M. Micheel,et al.  Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease , 2010 .

[67]  Eoin L. Brodie,et al.  Airway Microbiota and Pathogen Abundance in Age-Stratified Cystic Fibrosis Patients , 2010, PloS one.

[68]  C. Merlo,et al.  Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. , 2010, JAMA.

[69]  C. Goss,et al.  Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. , 2010, JAMA.

[70]  D. Porteous,et al.  Sputum and serum calprotectin are useful biomarkers during CF exacerbation. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[71]  Boris Freidlin,et al.  Randomized clinical trials with biomarkers: design issues. , 2010, Journal of the National Cancer Institute.

[72]  S. Willsie.  Lung Disease at Diagnosis in Infants with Cystic Fibrosis Detected by Newborn Screening , 2010 .

[73]  S. Willsie.  Inhaled Aztreonam Lysine For Chronic Airway Pseudomonas aeruginosa In Cystic Fibrosis , 2010 .

[74]  M. Field,et al.  Rare Diseases and Orphan Products: Accelerating Research and Development , 2010 .

[75]  J. Jais,et al.  A Novel Lipidomic Strategy Reveals Plasma Phospholipid Signatures Associated with Respiratory Disease Severity in Cystic Fibrosis Patients , 2009, PloS one.

[76]  P. Davis,et al.  The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[77]  R. Gibson,et al.  Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. , 2009, Chest.

[78]  J. Clancy,et al.  Potential role of high-mobility group box 1 in cystic fibrosis airway disease. , 2008, American journal of respiratory and critical care medicine.

[79]  C. Cotton,et al.  Dysfunction of Nrf-2 in CF Epithelia Leads to Excess Intracellular H2O2 and Inflammatory Cytokine Production , 2008, PloS one.

[80]  R. Gibson,et al.  A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection , 2008, Pediatric pulmonology.

[81]  M. Corey,et al.  High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. , 2007, The Journal of pediatrics.

[82]  M. Konstan,et al.  Sputum biomarkers of inflammation in cystic fibrosis lung disease. , 2007, Proceedings of the American Thoracic Society.

[83]  J. Elborn,et al.  The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation , 2007, Pediatric pulmonology.

[84]  R. Gibson,et al.  No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. , 2007, American journal of respiratory cell and molecular biology.

[85]  R. Kronmal,et al.  Association between pulmonary function and sputum biomarkers in cystic fibrosis. , 2007, American journal of respiratory and critical care medicine.

[86]  M. Corey,et al.  Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. , 2006, American journal of respiratory and critical care medicine.

[87]  Michael P Boyle,et al.  Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease. , 2006, American journal of respiratory cell and molecular biology.

[88]  T. Luider,et al.  Proteomic analysis of nasal cells from cystic fibrosis patients and non‐cystic fibrosis control individuals: Search for novel biomarkers of cystic fibrosis lung disease , 2006, Proteomics.

[89]  P. Bye,et al.  Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. , 2005, American journal of respiratory and critical care medicine.

[90]  M. Kosorok,et al.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. , 2005, JAMA.

[91]  Thomas R Fleming,et al.  Surrogate endpoints and FDA's accelerated approval process. , 2005, Health affairs.

[92]  M. Amaral,et al.  CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. , 2004, Gastroenterology.

[93]  K. Kunzelmann,et al.  Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[94]  R. Desnick.  Enzyme replacement therapy for Fabry disease: lessons from two α-galactosidase A orphan products and one FDA approval , 2004, Expert opinion on biological therapy.

[95]  J. Emerson,et al.  Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials , 2004, Pediatric pulmonology.

[96]  J. Uddin,et al.  Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway , 2004, Nature Immunology.

[97]  U. Wahn,et al.  Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. , 2004, American journal of respiratory and critical care medicine.

[98]  M. Amaral,et al.  Assessment of CFTR function in native epithelia for the diagnosis of cystic fibrosis , 2004, Pediatric pulmonology. Supplement.

[99]  R. Gibson,et al.  Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[100]  R. Gibson,et al.  Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management , 2003, Current opinion in pulmonary medicine.

[101]  B. Kerem,et al.  Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. , 2003, The New England journal of medicine.

[102]  L. Saiman,et al.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. , 2003, JAMA.

[103]  J. Emerson,et al.  Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[104]  P. Noone,et al.  Idiopathic Pancreatitis Related to CFTR: Complex Inheritance and Identification of a Modifier Gene , 2002, Journal of Investigative Medicine.

[105]  M. Knowles,et al.  Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. , 2001, Gastroenterology.

[106]  F. Accurso,et al.  Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. , 2001, American journal of respiratory and critical care medicine.

[107]  J. Clancy,et al.  Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. , 2001, American journal of respiratory and critical care medicine.

[108]  B. Strandvik,et al.  Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. , 2001, The European respiratory journal.

[109]  C. Cross,et al.  Myeloperoxidase and protein oxidation in cystic fibrosis. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[110]  B. Tümmler,et al.  Residual chloride secretion in intestinal tissue of deltaF508 homozygous twins and siblings with cystic fibrosis. The European CF Twin and Sibling Study Consortium. , 2000, Gastroenterology.

[111]  D. Zurakowski,et al.  Pulmonary Outcome in Cystic Fibrosis Is Influenced Primarily by Mucoid Pseudomonas aeruginosa Infection and Immune Status and Only Modestly by Genotype , 1999, Infection and Immunity.

[112]  M S Pepe,et al.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. , 1999, The New England journal of medicine.

[113]  P. Zeitlin,et al.  A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. , 1998, American journal of respiratory and critical care medicine.

[114]  M. Knowles,et al.  In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. , 1995, Human gene therapy.

[115]  P. J. Byard,et al.  Effect of high-dose ibuprofen in patients with cystic fibrosis. , 1995, The New England journal of medicine.

[116]  H. Fuchs,et al.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.

[117]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.